UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) by 54.5% during the fourth quarter, Holdings Channel reports. The fund owned 35,579 shares of the company’s stock after purchasing an additional 12,545 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in ORIC Pharmaceuticals were worth $287,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ORIC. Two Sigma Advisers LP raised its stake in ORIC Pharmaceuticals by 14.3% in the 4th quarter. Two Sigma Advisers LP now owns 66,500 shares of the company’s stock valued at $537,000 after purchasing an additional 8,300 shares during the last quarter. Tema Etfs LLC acquired a new position in shares of ORIC Pharmaceuticals in the fourth quarter valued at approximately $367,000. Sphera Funds Management LTD. raised its position in shares of ORIC Pharmaceuticals by 112.8% in the fourth quarter. Sphera Funds Management LTD. now owns 273,213 shares of the company’s stock valued at $2,205,000 after buying an additional 144,817 shares during the last quarter. ProShare Advisors LLC lifted its stake in shares of ORIC Pharmaceuticals by 30.9% during the fourth quarter. ProShare Advisors LLC now owns 20,683 shares of the company’s stock valued at $167,000 after buying an additional 4,881 shares during the period. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of ORIC Pharmaceuticals by 22.0% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,846 shares of the company’s stock valued at $1,411,000 after buying an additional 31,526 shares during the period. Hedge funds and other institutional investors own 95.05% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on ORIC. JPMorgan Chase & Co. lifted their target price on shares of ORIC Pharmaceuticals from $21.00 to $22.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Guggenheim reaffirmed a “buy” rating on shares of ORIC Pharmaceuticals in a research note on Wednesday, February 26th. HC Wainwright reiterated a “buy” rating and issued a $21.00 price target on shares of ORIC Pharmaceuticals in a report on Monday, May 5th. Cantor Fitzgerald restated an “overweight” rating on shares of ORIC Pharmaceuticals in a report on Tuesday, May 6th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $20.00 target price on shares of ORIC Pharmaceuticals in a research report on Thursday, May 29th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $19.17.

ORIC Pharmaceuticals Stock Up 3.0%

ORIC opened at $9.67 on Friday. ORIC Pharmaceuticals, Inc. has a 52-week low of $3.90 and a 52-week high of $14.67. The company has a 50 day moving average of $6.04 and a two-hundred day moving average of $7.71. The company has a market cap of $687.42 million, a P/E ratio of -5.31 and a beta of 1.49.

ORIC Pharmaceuticals (NASDAQ:ORIC) last posted its earnings results on Monday, May 5th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.09. Research analysts anticipate that ORIC Pharmaceuticals, Inc. will post -2.17 earnings per share for the current year.

Insider Buying and Selling at ORIC Pharmaceuticals

In other news, CFO Dominic Piscitelli sold 2,976 shares of the company’s stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $10.01, for a total value of $29,789.76. Following the completion of the sale, the chief financial officer now owns 102,117 shares of the company’s stock, valued at $1,022,191.17. This represents a 2.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 6,200 shares of company stock valued at $62,056 over the last three months. 6.82% of the stock is owned by company insiders.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.